 Receptor, erbB-2
"Receptor, erbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.
| Descriptor ID |
D018719
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.150 D12.776.543.750.060.374 D12.776.543.750.750.400.350 D12.776.624.664.700.642 D23.101.840.642
|
| Concept/Terms |
Receptor, erbB-2- Receptor, erbB-2
- Receptor, erbB 2
- erbB-2 Receptor
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- Receptors, erbB-2
- Receptors, erbB 2
- erbB-2 Receptors
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- p185(c-neu)
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- Receptor, neu
- c-erbB-2 Protein
- c erbB 2 Protein
- neu Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, erbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, erbB-2 [D08.811.913.696.620.682.725.400.150]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, erbB-2 [D12.776.543.750.060.374]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptor, erbB-2 [D12.776.543.750.750.400.350]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, erbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Biological Markers [D23.101]
- Tumor Markers, Biological [D23.101.840]
- Receptor, erbB-2 [D23.101.840.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, erbB-2".
This graph shows the total number of publications written about "Receptor, erbB-2" by people in UAMS Profiles by year, and whether "Receptor, erbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 1 | 1 | | 2024 | 0 | 2 | 2 | | 2022 | 0 | 2 | 2 | | 2021 | 1 | 2 | 3 | | 2020 | 2 | 1 | 3 | | 2019 | 1 | 4 | 5 | | 2018 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2015 | 0 | 3 | 3 | | 2014 | 0 | 3 | 3 | | 2013 | 2 | 4 | 6 | | 2012 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2008 | 4 | 0 | 4 | | 2007 | 1 | 2 | 3 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 1 | 3 | | 2004 | 1 | 2 | 3 | | 2003 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, erbB-2" by people in Profiles over the past ten years.
-
Landi D, Navai SA, Brock RM, Fousek K, Nawas Z, Sanber K, Chauvin-Fleurence C, Bhat RR, Xu S, Krishnamurthy P, Choe M, Campbell ME, Morris JS, Gad AZ, Shree A, Echeandia Marrero AS, Saadeldin AM, Matthew PR, Mullikin D, Bielamowicz K, Kurenbekova L, Major AM, Salsman VS, Byrd TT, Hicks JM, Zhang YJ, Yustein J, Carisey AF, Joseph SK, Ahmed N, Hegde M. A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 Mar 01; 5(3):527-548.
-
Strand SH, Houlahan KE, Branch V, Lynch T, Rivero-Guiti?rrez B, Harmon B, Couch F, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe P, Curtis C, Owzar K, Marks JR, Colditz GA, Hwang ES, West RB. Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome. Breast Cancer Res. 2024 Sep 02; 26(1):127.
-
An SJ, Thai CHNC, Ismail S, Agala CB, Hoang V, Feeney T, Lillie M, Wheless A, Selfridge JM, Ollila DW, Gallagher KK, Carey LA, Spanheimer PM. Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution. Ann Surg Oncol. 2024 Dec; 31(13):8786-8794.
-
Bui OT, Tran HT, Nguyen SM, Dao TV, Bui QV, Pham AT, Shrubsole MJ, Cai Q, Ye F, Zheng W, Luu HN, Tran TV, Shu XO. Menstrual and Reproductive Factors in Association With Breast Cancer Risk in Vietnamese Women: A Case-Control Study. Cancer Control. 2022 Jan-Dec; 29:10732748221140206.
-
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
-
Iles KA, Thornton M, Park J, Roberson M, Spanheimer PM, Ollila DW, Gallagher K. Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe? Am Surg. 2022 Mar; 88(3):471-479.
-
Kundumani-Sridharan V, Subramani J, Owens C, Das KC. Nrg1? Released in Remote Ischemic Preconditioning Improves Myocardial Perfusion and Decreases Ischemia/Reperfusion Injury via ErbB2-Mediated Rescue of Endothelial Nitric Oxide Synthase and Abrogation of Trx2 Autophagy. Arterioscler Thromb Vasc Biol. 2021 08; 41(8):2293-2314.
-
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021 05; 71(3):264-279.
-
Grova MM, Strassle PD, Navajas EE, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Apr; 28(4):2182-2190.
-
Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol. 2020 10; 159(1):17-22.
-
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 06; 21(6):821-831.
-
Downs-Canner SM, Gaber CE, Louie RJ, Strassle PD, Gallagher KK, Muss HB, Ollila DW. Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer. Cancer. 2020 03 15; 126(6):1193-1201.
-
Horta E, Bongiorno C, Ezzeddine M, Neil EC. Neurotoxicity of antibodies in cancer therapy: A review. Clin Neurol Neurosurg. 2020 01; 188:105566.
-
Gallagher KK, Ollila DW. Indications for Neoadjuvant Systemic Therapy for Breast Cancer. Adv Surg. 2019 09; 53:271-292.
-
Farra C, Fedda F, Tfayli A, Tawil A, Zaatari G, Ashkar H, Issa G, Boulos F. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer. Clin Breast Cancer. 2019 10; 19(5):340-344.
-
Petimar J, Park YM, Smith-Warner SA, Fung TT, Sandler DP. Dietary index scores and invasive breast cancer risk among women with a family history of breast cancer. Am J Clin Nutr. 2019 05 01; 109(5):1393-1401.
-
Kumarapeli AR, Bellamy W, Olgaard E, Massoll N, Korourian S. Short-Duration Rapid Chilling of Mastectomy Specimens Does Not Interfere With Breast Cancer Biomarker and Molecular Testing. Arch Pathol Lab Med. 2019 01; 143(1):92-98.
-
Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discov. 2018 06; 8(6):686-695.
-
Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
-
Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
-
Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
-
Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol. 2016 06; 39(3):248-54.
-
Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8).
-
Erdem H, Gundogdu B, Ankarali H, Yasar M, Sener E, Oktay M, Bahadir A, Uzunlar AK, Gursan N, Ozaydin I, Sahiner C. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms. Niger J Clin Pract. 2015 Sep-Oct; 18(5):638-43.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|